Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies develops regenerative medicine products using cell and tissue protocols, primarily involving adult stem cells. News about BRTX centers on BRTX-100, its autologous hypoxic-cultured mesenchymal stem cell therapy for chronic lumbar disc disease, including clinical trial updates, safety and efficacy data presentations, and regulatory interactions tied to the program.
The company also reports developments involving its ThermoStem metabolic program and its commercial BioCosmeceutical platform. Recurring updates include scientific conference presentations, collaborations supporting BioCosmeceutical commercialization, capital actions, shareholder communications, and business updates related to development spending and platform expansion.
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has announced it will release its Q1 2025 financial results on Wednesday, May 14, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET to discuss the financial results and provide a business update. Investors can join via domestic (1-888-506-0062) or international (1-973-528-0011) lines using access code 924151. The call will be broadcast live and archived on the company's website in the Investors section.
BioRestorative Therapies (NASDAQ:BRTX) has announced that its Vice President of Research and Development, Francisco Silva, will present an update on the company's ongoing Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease (cLDD) at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting. The presentation, titled "Phase 2 Clinical Safety/Efficacy Data of Intradiscal Injection of Hypoxic Mesenchymal Stem Cells for Lumbar Disc Disease," will take place on Thursday, May 8, from 3:45-4:45 pm CT at the conference in New Orleans, LA.
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has announced its CEO Lance Alstodt will participate in the Benzinga All-Access Show on April 15, 2025, at 10:50 a.m. Eastern time.
During the interview, the company plans to discuss their recent achievements in clinical and regulatory milestones, along with highlighting commercial opportunities. The session will be accessible via live webcast and will subsequently be archived in the Investors section of the company's website.
BioRestorative Therapies (NASDAQ:BRTX) confirms no material impact from new U.S. tariffs due to its domestic production strategy for BRTX-100, its lead cell-based therapeutic targeting areas with blood flow. The company reports significant clinical progress with:
- FDA Fast Track designation for BRTX-100 in treating chronic lumbar disc disease (cLDD), following positive Phase 2 preliminary data
- FDA clearance of IND application for BRTX-100 in treating chronic cervical discogenic pain (cCDP)
- Strong financial position with over $10 million in cash, cash equivalents, and marketable securities at the end of 2024
BioRestorative Therapies (NASDAQ:BRTX) reported significant financial improvements for 2024, with total revenue increasing 175% to $401,000 from $146,000 in 2023. The company reduced its operating loss by 24% to $11.6 million and improved net loss by 14% to $9.0 million ($1.16 per share).
Key developments include:
- FDA Fast Track designation for BRTX-100 program for chronic lumbar disc disease (cLDD) treatment
- FDA clearance for BRTX-100 IND application for chronic cervical discogenic pain
- Provisional license from NY State Department of Health for allogeneic tissue processing
- Positive preliminary Phase 2 trial data for BRTX-100 showing no serious adverse events
The company ended 2024 with $10.7 million in cash and investments, with no outstanding debt. BioCosmeceuticals generated $300,000 in revenue for 2024.
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has scheduled the release of its 2024 financial results for Thursday, March 27, 2025, after market close. The company's management team will conduct a conference call following the announcement to discuss the financial performance and provide updates on business operations.
Investors and interested parties can access the live broadcast and archived recording of the conference call through the company's website at biorestorative.com/investor-relations under the Events section.
BioRestorative Therapies (NASDAQ:BRTX) has received FDA clearance for its Investigational New Drug (IND) application for BRTX-100, marking a significant advancement in stem cell-based therapies. The treatment, designed to target areas with blood flow, will be evaluated for chronic cervical discogenic pain (cCDP) in a Phase 2 trial.
BRTX-100 represents the first and only stem cell product candidate cleared for evaluation in cervical degenerative disc disease. This expansion builds upon the company's existing FDA Fast Track-designated program for chronic lumbar disc disease (cLDD). The upcoming Phase 2 study will be conducted as a double-blind, sham-controlled, randomized trial to assess safety and preliminary efficacy of intradiscal BRTX-100 injections.
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has rescheduled its webcasted conference call to discuss pipeline updates. The call will now take place on Thursday, February 27, 2025, at 10:30am EST.
Participants can join via telephone by dialing 888-506-0062 (US) or 973-528-0011 (International) using access code 440089. The conference call will be broadcast live and archived in the Investor Relations section of the company's website at biorestorative.com.
BioRestorative Therapies (NASDAQ:BRTX) has announced it will provide a positive clinical pipeline update before market open on Thursday, February 27, 2025. The regenerative medicine company, which focuses on stem cell-based therapies, will share what CEO Lance Alstodt describes as "meaningful key developments" regarding their clinical pipeline.
Alstodt expressed enthusiasm about the upcoming announcement, noting that it reflects "the very solid work of our scientific team over the last several years come to fruition" and mentioned additional positive events related to BRTX-100, one of the company's products.
The company will host a webcasted conference call at 8:00am EST on February 27, 2025, accessible by dialing 888-506-0062 (US) or 973-528-0011 (International) with participant access code 440089. The call will also be broadcast live and archived on the Investor section of BioRestorative's website.